Factor IX variants and uses thereof in therapy
Grant
US12577552B2
Kind: B2
Mar 17, 2026
Assignee
CSL Innovation Pty Ltd
Inventors
Philipp Claar, Thomas Weimer, Walid Azar, Holger Lind, Marco Hofmann
Abstract
This invention provides Factor IX variants, molecules comprising the variants, nucleic acids encoding the variants, compositions comprising the variants or the nucleic acids encoding the variants, and their use in methods for the modulation of hemostasis, for example in the prophylaxis or treatment of hemophilia B. The Factor IX variants have improved biological properties relative to other Factor IX variants and/or relative to wild-type Factor IX.
CPC Classifications
C12N 9/644
A61K 38/4846
C12Y 304/21022
Filing Date
2020-03-18
Application No.
17440281
Claims
11